- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01:03 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| Di | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| Di | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| Fr | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| Do | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 26.08. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 24.08. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 1 | ASX | ||
| VITA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 20.08. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 19.08. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | 2 | ASX | ||
| 18.08. | Vita Life Sciences Delivers Record First Half on Improved Product Mix and Margin Increase | 1 | smallcaps.com.au | ||
| 18.08. | VITA LIFE SCIENCES LIMITED: Half Year Presentation | 1 | ASX | ||
| 17.08. | Vita Life Sciences Ltd Profit Climbs In H1 | 2 | RTTNews | ||
| 17.08. | VITA LIFE SCIENCES LIMITED: Dividend/Distribution - VLS | 1 | ASX | ||
| 17.08. | VITA LIFE SCIENCES LIMITED: Half Yearly Report and Accounts | - | ASX | ||
| 02.07. | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 30.06. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 29.06. | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 19.06. | VITA LIFE SCIENCES LIMITED: Cleasing Statement | - | ASX | ||
| 19.06. | VITA LIFE SCIENCES LIMITED: Application for quotation of securities - VLS | - | ASX | ||
| 12.06. | VITA LIFE SCIENCES LIMITED: Guidance | - | ASX |
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GREEN THUMB INDUSTRIES | 6,460 | +1,73 % | Green Thumb Industries Stock Looks Stuck. Here's Why Wall Street Loves the Cannabis Stock Anyway. | ||
| NEKTAR THERAPEUTICS | 60,88 | -1,77 % | Nektar Therapeutics Announces Second Quarter 2026 Financial Results | SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 228,10 | +7,44 % | Alnylam Pharmaceuticals, Inc.: Alnylam präsentiert auf dem ESC Congress 2026 neue Daten, die die Wirksamkeit des RNAi-basierten TTR-Silencing bei verschiedenen ATTR-CM-Patientengruppen und in verschiedenen Behandlungsumgebungen belegen | Eine kürzlich durchgeführte, vorab festgelegte Subgruppenanalyse der HELIOS-B-Studie zeigt, dass Vutrisiran bei Patienten mit oder ohne Behandlung mit Tafamidis zu Studienbeginn einen konsistenten... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,722 | 0,00 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| ADASTRA | 0,127 | -100,00 % | CSE Bulletin: Suspensions - Adastra Holdings Ltd., CAT Strategic Metals Corporation, Greenrise Global Brands Inc., StickIt Technologies Inc. | Le 12 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 11,950 | +4,37 % | Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here | ||
| ACADIA PHARMACEUTICALS | 24,860 | -0,24 % | Acadia Pharmaceuticals Inc.: European Commission Approves DAYBU (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| MOLECULE HOLDINGS | 0,001 | 0,00 % | Molecule Holdings Inc: Molecule receives partial revocation order of FFCTO | ||
| NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 23.04.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.04.2026ISIN NameAU000000BMG3 BMG... ► Artikel lesen | |
| OPUS GENETICS | 3,500 | +5,42 % | Wichtige Studiendaten treiben Aktie von Opus Genetics an | ||
| ANI PHARMACEUTICALS | 62,00 | -0,80 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors | - Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company - PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company)... ► Artikel lesen | |
| SOLIGENIX | 0,381 | +1,28 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results | PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| SAVARA | 4,506 | -0,73 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen |
Das Unternehmen VITA LIFE SCIENCES LIMITED kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.